Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis.
Mammalian cells undergo cell cycle arrest in response to DNA damage due to the existence of multiple checkpoint response mechanisms. One such checkpoint pathway operating at the G(1) phase is frequently lost in cancer cells due to mutation of the p53 tumor suppressor gene. However, cancer cells often arrest at the G(2) phase upon DNA damage, due to activation of another checkpoint pathway that prevents the activation Cdc2 kinase. The kinases, Chk1, Wee1, and Myt1 are key regulators of this G(2) checkpoint, which act directly or indirectly to inhibit Cdc2 activity. Here we show that RNA interference (RNAi)-mediated downregulation of Wee1 kinase abrogated an Adriamycin trade mark -induced G(2) checkpoint in human cervical carcinoma Hela cells that are defective in G(1) checkpoint response. Wee1 downregulation sensitized HeLa cells to Adriamycin trade mark -induced apoptosis. Downregulation of Chk1 kinase in Hela cells also caused a significant amount of cell death in dependent of DNA damage. In contrast, Myt1 downregulation also abrogated Adriamycin trade mark -induced G(2) arrest but did not cause substantial apoptosis. Reduction in Wee1, Chk1, or Myt1 levels did not sensitize normal human mammary epithelial cells (HMEC) cells to Adriamycin trade mark -induced apoptosis unlike the situation in Hela cells. Our study reveals distinct roles for Chk1, Wee1, and Myt1 in G(2) checkpoint regulation. The data reported here support the attractiveness of Wee1 and Chk1 is as molecular targets for abrogating the G(2) DNA damage checkpoint arrest, a situation that may selectively sensitize p53-deficient tumor cells to radiation or chemotherapy treatment.
Wang
Yuli
Y
Cancer Molecular Sciences Department, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, Michiagan, USA. yuli.wang@pfizer.com
Decker
Stuart J
SJ
Sebolt-Leopold
Judith
J
D017209:Apoptosis / Q000235:genetics*; D001940:Breast / Q000166:cytology; D018797:Cell Cycle Proteins; D000071877:Checkpoint Kinase 1; D004249:DNA Damage; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000494:pharmacology; D015536:Down-Regulation; D004847:Epithelial Cells; D005260:Female; D016195:G2 Phase; D006367:HeLa Cells; D006801:Humans; D018991:Myelin Proteolipid Protein; D009687:Nuclear Proteins; D011494:Protein Kinases / Q000096:biosynthesis* / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases; D034622:RNA Interference; D014157:Transcription Factors / Q000096:biosynthesis* / Q000494:pharmacology
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; C078341:MYT1 protein, human; D018991:Myelin Proteolipid Protein; D009687:Nuclear Proteins; D014157:Transcription Factors; D011494:Protein Kinases; D011505:Protein-Tyrosine Kinases; C499349:WEE1 protein, human; C000605867:CHEK1 protein, human; D000071877:Checkpoint Kinase 1